Osimertinib

Osimertinib is a prescription targeted cancer medicine used to treat certain types of non-small cell lung cancer (NSCLC). It belongs to a group of medicines called epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Osimertinib works by blocking abnormal EGFR signalling that can help cancer cells grow and divide.

The suitability of osimertinib depends on the type of lung cancer, the tumour’s genetic characteristics, previous treatment and the patient’s overall medical condition. This page provides general educational information and an overview of the osimertinib products listed by DrMeds.org.

What Is Osimertinib Used For?

Osimertinib is used for specific forms of NSCLC associated with particular EGFR gene changes. These include EGFR exon 19 deletions and exon 21 L858R mutations. Depending on the applicable product approval and treatment setting, it may be used after surgery, following chemoradiation for certain locally advanced cancers, or to treat advanced or metastatic disease.

It is also approved in certain settings for metastatic NSCLC with an EGFR T790M mutation that has progressed during or after earlier EGFR tyrosine kinase inhibitor treatment.

In some treatment settings, osimertinib is prescribed alone. In others, it may be combined with platinum-based chemotherapy and pemetrexed. The appropriate treatment depends on the patient’s diagnosis, test results, previous therapy and the relevant prescribing guidelines.

Important: Osimertinib is not suitable for every type of lung cancer. Testing for relevant EGFR mutations is an important part of determining whether this medicine may be appropriate.

How Does Osimertinib Work?

EGFR is a protein involved in signalling pathways that regulate cell growth and survival. Certain EGFR mutations can cause these signals to remain abnormally active, contributing to cancer development.

Osimertinib inhibits specific abnormal EGFR signalling, helping control the growth and survival of cancer cells that depend on these changes. Its activity against particular EGFR mutations makes it a targeted therapy rather than a conventional cytotoxic chemotherapy medicine.

Treatment response varies between patients. A cancer specialist evaluates the expected benefits, possible risks and appropriate monitoring throughout treatment.

Available Osimertinib Products at DrMeds.org

DrMeds.org lists the following osimertinib products:

Each product has its own listing. Visit the respective product page to review the available product details, manufacturer information and enquiry options.

Although both products contain the same active ingredient and listed strength, patients should not assume that products are interchangeable without verification by a qualified healthcare professional. Product quality, authenticity, regulatory status and the applicable product information should be confirmed through authorised supply channels.

Product listings do not guarantee current stock or immediate availability. Contact DrMeds.org to enquire about product details, availability, prescription requirements and applicable delivery arrangements.

Important Safety Information

Osimertinib can cause side effects, including some that may be serious. Commonly reported adverse effects include diarrhoea, skin rash, dry skin and nail changes. The likelihood and severity of side effects vary among patients.

Important risks include:

  • Lung inflammation: Interstitial lung disease or pneumonitis can occur. New or worsening cough, fever or shortness of breath requires prompt medical assessment.
  • Heart problems: Osimertinib may affect the electrical activity of the heart and, in some patients, heart function. Monitoring may be needed according to individual risk and the prescribing information.
  • Eye problems: Inflammation of the cornea and other eye-related adverse effects can occur. Report eye pain, redness, light sensitivity or changes in vision.
  • Severe skin reactions: Rare but serious skin reactions have been reported and require urgent medical evaluation.
  • Blood-related complications: Changes in blood counts, including rare serious bone marrow problems, may require monitoring.

Before starting treatment, patients should tell their healthcare professional about existing medical conditions, all medicines and supplements they take, and any history of heart or lung problems. Osimertinib can interact with other medicines, so medication review is important.

Pregnancy and breastfeeding require specific medical guidance because the medicine may harm an unborn baby and breastfeeding is not recommended during treatment under the referenced US prescribing information.

Patients should follow the prescribed treatment plan and should not alter or stop treatment without medical advice. Severe breathing difficulty, fainting, a rapid or irregular heartbeat with concerning symptoms, or a serious skin reaction warrants urgent medical attention.

Frequently Asked Questions

What is osimertinib used for?

Osimertinib is used for specific types of EGFR-mutated non-small cell lung cancer. Its approved uses depend on the tumour’s genetic changes, disease stage, previous treatment and local product approval.

Is osimertinib a chemotherapy medicine?

Osimertinib is classified as a targeted therapy called an EGFR tyrosine kinase inhibitor. It may be used alone or alongside chemotherapy in certain treatment settings.

What strength of osimertinib is listed on DrMeds.org?

The molecule page lists LuciOsim Osimertinib 80 mg Tablet and Osimert Osimertinib 80 mg Tablet. Refer to the individual listings for product-specific details.

Is EGFR testing required before treatment?

Testing for relevant EGFR mutations is essential to selecting patients for the approved uses described above. A cancer specialist will determine which tests are appropriate and interpret the results.

What are the important side effects of osimertinib?

Diarrhoea, skin rash, dry skin and nail changes can occur. More serious risks include lung inflammation and heart-related complications. Seek medical advice promptly if new or concerning symptoms develop.

How can I enquire about osimertinib products?

Visit the individual product listings on DrMeds.org and use the available contact or enquiry options to request current product information, availability and prescription requirements.

Medical Disclaimer

This page is intended for general educational purposes only and does not replace professional medical advice, diagnosis or treatment. Osimertinib should be used only under the supervision of a qualified cancer specialist. Always consult the prescribing information applicable to the specific product and country.

Medical References

  1. National Cancer Institute (NCI). Osimertinib Mesylate — Drug Information. https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib
  2. U.S. National Library of Medicine, DailyMed. TAGRISSO (osimertinib) — Official Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7
  3. U.S. Food and Drug Administration (FDA). FDA Approves Osimertinib with Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer

Content review date: 23 October 2026
Medical review status: Pending review by a qualified medical professional before publication.

Showing all 4 results

Shopping Cart
Scroll to Top